Comparison of the Effectiveness of Drotaverine Hydrochloride and Valethamate Bromide in Promoting Cervical Dilatation during Active Labour: An Observational study.

Background: Cervical dilatation is an essential aspect of active labour, which is necessary for the progress of delivery. Delayed or inadequate cervical dilatation can lead to prolonged labour, fetal distress, and the need for instrumental delivery. Pharmacological agents, such as Drotaverine Hydrochloride and Valethamate Bromide, are commonly used to promote cervical dilatation and facilitate delivery. Aim: To Observe the effectiveness of Drotaverine Hydrochloride and Valethamate Bromide in Promoting Cervical Dilatation during Active Labour. Methodology: This was a randomized, observational study conducted at a tertiary care hospital. A total of 100 women in active labour, with a cervical dilatation of less than 4 cm, were included in the study. They were randomly divided into two groups, with 50 women in each group. The first group received Drotaverine Hydrochloride, while the second group received Valethamate Bromide. The drugs were administered intravenously as per the standard protocol. The rate of cervical dilatation was monitored in both groups for a period of 6 hours. Results: The mean rate of cervical dilatation in the Drotaverine Hydrochloride group was 1.7 cm/hour, while in the Valethamate Bromide group it was 1.2 cm/hour. The difference was statistically significant (p<0.05). The mean time for cervical dilatation of 4 cm was 2.5 hours in the Drotaverine Hydrochloride group, while in the Valethamate Bromide group it was 3.5 hours. The difference was statistically significant (p<0.05). The adverse effects observed in both groups were similar and mild. Conclusion: In this observational study, Drotaverine Hydrochloride was found to be more effective in promoting cervical dilatation during active labour as compared to Valethamate Bromide. However, further studies are needed to validate these findings and to explore the long-term effects of these drugs on maternal and fetal outcomes. [ABSTRACT FROM AUTHOR]